Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Biosite in Cardiovascular Biomarker Collaboration

NEW YORK, Feb. 10 - Ciphergen Biosystems and Biosite have begun a collaboration to discover antibody and protein target components for use in diagnostic assays for cardiovascular disease, the companies said today.

 

Biosite will provide clinical samples that Ciphergen scientists will analyze using its ProteinChip technology. The companies will search for differentially expressed protein biomarkers that may be useful as diagnostics or with therapeutic potential.

 

Biosite plans to develop antibodies against key biomarkers discovered in this collaboration. Both firms are entitled to royalties from any products successfully developed and commercialized as a result of the research.

 

The project will initially focus on cardiovascular disease, an area in which Biosite has already commercialized several diagnostic systems.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.